Reduction of Myocardial Necrosis after Glycosaminoglycan Administration: Effects of a Single Intravenous Administration of Heparin or N-Acetylheparin 2 Hours before Regional Ischemia and Reperfusion

Simpson P.J. , Mickelson J. , Fantone J.C. , Gallagher K.P. , Lucchesi B.R. Iloprost inhibits neutrophil function in vitro and in vivo and limits experimental infarct size in canine heart. Circ Res 60: 666, 1987

Simpson P.J. , Fantone J.C. , Mickelson J.K. , Gallagher K.P. , Lucchesi B.R. Identification of a time window for therapy to reduce experimental canine myocardial injury: suppression of neutrophil activation during 72 hours of reperfusion. Circ Res 63: 1070, 1988

Simpson P.J. , Todd R.F. , Mickelson J.K. , Sustained limitation of myocardial reperfusion injury by a monoclonal antibody that alters leukocyte function. Circulation 81: 226, 1990

Kawamura T. , Wakusawa R. , Okada K. , Inada S. Elevation; of cytokines during open heart surgery with cardiopulmonary bypass: participation of interleukin 8 and 6 in reperfusion injury. Can J Anaesth 40: 1016, 1993

Steinberg J.B. , Kapelanski D.P. , Olson J.D. , Weiler J.M. Cytokine and complement levels in patients undergoing cardiopulmonary bypass. J Thorac Cardiovasc Surg 106: 1008, 1993

Latini R. , Bianchi M. , Correale E Cytokines in acute myocardial infarction: selective increase in circulating tumor necrosis factor, its soluble receptor, and interleukin-1 receptor antagonist. J Cardiovasc Pharmacol 23: 1, 1994

Pinckard R.N. , Olson M.S. , Giclas P.C. , Terry R. , Boyer J.T. , O'Rourke R.A. Consumption of classical complement components by heart subcellular membranes in vitro and in patients after acute myocardial infarction. J Clin Invest 56: 740, 1975

Schafer H. , Mathey D. , Hugo F. , Bhakdi S. Deposition of the terminal C5b-9 complement complex in infarcted areas of human myocardium. J Immunol 137: 1945, 1986

Rossen R.D. , Michael L.H. , Kagiyama A Mechanism of complement activation after coronary artery occlusion: evidence that myocardial ischemia in dogs causes release of constituents of myocardial subcellular origin that complex with human Clq in vivo. Circ Res 62: 572, 1988

Yasuda M. , Kawarabayashi T. , Akioka K The complement system in the acute phase of myocardial infarction. Jpn Circ J 53: 1017, 1989

Mathey D. , Schofer J. , Schafer H.J. , Early accumulation of the terminal complement-complex in the ischaemic myocardium after reperfusion. Eur Heart J 15: 418, 1994

Hill J.H. , Ward P.A. The phlogistic role of C3 leukotactic fragments in myocardial infarcts of rats. J Exp Med 133: 885, 1971

Rus H.G. , Niculescu F. , Vlaicu R. Presence of C5b-9 complement complex and S-protein in human myocardial areas with necrosis and sclerosis. Immunol Lett 16: 15, 1987

Hugo F. , Hamdoch T. , Mathey D. , Schafer H. , Bhakdi S. Quantitative measurement of SC5b-9 and C5b-9(m) in infarcted areas of human myocardium. Clin Exp Immunol 81: 132, 1990

Lu C.Y. , Khair-el-Din T.A. , Dawidson I.A. , Xenotransplantation. FASEB J 8: 1122, 1994

Ecker E.E. , Gross P. Anticomplementary power of heparin. J Infect Dis 44: 250, 1929

Rent R. , Ertel N. , Eisenstein R. , Gewurz H. Complement activation by interaction of polyanions and polycations. I: heparin–protamine-induced consumption of complement. J Immunol 114: 120, 1975

Baker P.J. , Lint T.F. , McLeod B.C. , Behrends C.L. , Gewurz H. Studies on the inhibition of C56-induced lysis (reactive lysis). VI. Modulation of C56-induced lysis polyanions and polycations. J Immunol 114: 554, 1975

Nagaki K. , Inai S. Inactivator of the first component of human complement (C1INA). Enhancement of C1INA activity against Cls by acidic mucopolysaccharides. Int Arch Allergy Appl Immunol 50: 172, 1976

Loos M. , Volanakis J.E. , Stroud R.M. Mode of interaction of different polyanions with the first (C1, C1), the second (C2) and the fourth (C4) component of complement—II: effect of polyanions on the binding of C2 to EAC4b. Immunochemistry 13: 257, 1976

Raepple E. , Hill H.U. , Loos M. Mode of interaction of different polyanions with the first (C1, C1), the second (C2) and the fourth (C4) component of complement—I: effect on fluid phase C1 and on C1 bound to EA or to EAC4. Immunochemistry 13: 251, 1976

Weiler J.M. , Yurt R.W. , Fearon D.T. , Austen K.F. Modulation of the formation of the amplification convertase of complement, C3b, Bb, by native and commercial heparin. J Exp Med 147: 409, 1978

Sharath M.D. , Merchant Z.M. , Kim Y.S. , Rice K.G. , Linhardt R.J. , Weiler J.M. Small heparin fragments regulate the amplification pathway of complement. Immunopharmacology 9: 73, 1985

Meri S. , Pangburn M.K. Discrimination between activators and nonactivators of the alternative pathway of complement: regulation via a sialic acid/polyanion binding site on factor H. Proc Natl Acad Sci U S A 87: 3982, 1990

Meri S. , Pangburn M.K. Regulation of alternative pathway complement activation by glycosaminoglycans: specificity of the polyanion binding site on factor H. Biochem Biophys Res Commun 198: 52, 1994

Edens R.E. , Linhardt R.J. , Bell C.S. , Weiler J.M. Heparin and derivatized heparin inhibit zymosan and cobra venom factor activation of complement in serum. Immunopharmacology 27: 145, 1994

Weiler J.M. , Edens R.E. , Linhardt R.J. , Kapelanski D.P. Heparin and modified heparin inhibit complement activation in vivo. J Immunol 148: 3210, 1992

Friedrichs G.S. , Kilgore K.S. , Manley P.J. , Gralinski M.R. , Lucchesi B.R. Effects of heparin and N-acetyl heparin on ischemia/reperfusion-induced alterations in myocardial function in the rabbit isolated heart. Circ Res 75: 701, 1994

Black S.C. , Gralinski M.R. , Friedrichs G.S. , Kilgore K.S. , Driscoll E.M. , Lucchesi B.R. Cardioprotective effects of heparin or N-acetylheparin in an in vivo model of myocardial ischaemic and reperfusion injury. Cardiovasc Res 29: 629, 1995

Romson J.L. , Hook B.G. , Kunkel S.L. , Abrams G.D. , Schork M.A. , Lucchesi B.R. Reduction of the extent of ischemic myocardial injury by neutrophil depletion in the dog. Circulation 67: 1016, 1983

Reimer K.A. , Jennings R.B. , Cobb F.R. , Animal models for protecting ischemic myocardium: results of the NHLBI Cooperative Study: comparison of unconscious and conscious dog models. Circ Res 56: 651, 1985

Jacques L.B. Heparin: an old drug with a new paradigm. Science 206: 528, 1979

Saliba M. Jr. , Covell J.W. , Bloor C.M. Effects of heparin in large doses on the extent of myocardial ischemia after acute coronary occlusion in the dog. Am J Cardiol 37: 599, 1976

Libersan D. , Khalil A. , Quan E. , Kallaayoune R. , Tran D. , Latour J.G. The low molecular weight heparin: exoxaparin reduces infarct size when given at reperfusion in untreated and streptokinase-treated dogs. J Mol Cell Cardiol 25 (suppl III): S90, 1993

Curtis M.J. (ed). The Handbook of Immunopharmacology: Immunopharmacology of the Heart. Academic Press London, 1993

McManus L.M. , Kolb W.P. , Crawford M.H. , O'Rourke R.A. , Grover F.L. , Pinckard R.N. Complement localization in ischemic baboon myocardium. Lab Invest 48: 436, 1983

Weisman H.F. , Bartow T. , Leppo M.K. , Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing postischemic myocardial inflammation and necrosis. Science 249: 146, 1990

Smith E.F. , Griswold D.E. , Egan J.W. , Reduction of myocardial reperfusion injury with human soluble complement receptor type 1 (BRL 55730). Eur J Pharmacol 236: 477, 1993

Boackle R.J. , Caughman G.B. , Vesely L. , Medgyesi G. , Fudenberg H.H. Potentiation of factor H by heparin: a rate-limiting mechanism for inhibition of the alternative complement pathway. Mol Immunol 20: 1157, 1983

Pangburn M.K. , Atkinson M.A. , Meri S. Localization of the heparin-binding site on complement factor H. J Biol Chem 266: 16847, 1991

Koistinen V. Effects of sulphated polyanions on functions of complement factor H. Mol Immunol 30: 113, 1993

Pasini F.L. , Pasqui A.L. , Ceccatelli L. , Capecchi P.L. , Orrico A. , Perri T.D. Heparin inhibition of polymorphonuclear leukocyte activation in vitro. A possible pharmacological approach to granulocyte-mediated vascular damage. Thromb Res 35: 527, 1984

Evangelista V. , Piccardoni P. , Maugeri N. , De Gaetano G. , Cerletti C. Inhibition by heparin of platelet activation induced by neutrophil-derived cathepsin G. Eur J Pharmacol 216: 401, 1992

Rajtar G. , Marchi E. , de Gaetano G. , Cerletti C. Effects of glycosaminoglycans on platelet and leucocyte function: role of N-sulfation. Biochem Pharmacol 46: 958, 1993

Bazzoni G. , Beltran Nunez A. , Mascellani G. , Bianchini P. , Dejana E.D. , Maschio A. Effect of heparin, dermatan sulfate, and related oligo-derivatives on human polymorphonuclear leukocyte functions. J Lab Clin Med 121: 268, 1993